Aleksandra Zgierska1, Margaret L Wallace2, Cindy A Burzinski3, Jennifer Cox4, Miroslav Backonja5. 1. Assistant Professor, Department of Family Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin. 2. Research Fellow, Department of Family Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin. 3. Assistant Researcher, Department of Family Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin. 4. Research Specialist, Department of Family Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin. 5. Department of Family Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin; Clinical Research Company Lifetree, Salt Lake City, Utah.
Abstract
OBJECTIVE:Refractory chronic low back pain (CLBP) often leads to treatment with long-term opioids. Our goal was to describe the pharmaco-toxicological profile of opioid-treated CLBP patients and identify potential areas for care optimization. DESIGN: Cross-sectional analysis. SETTING: Outpatient primary care. PARTICIPANTS: CLBP patients prescribed ≥ 30 mg/d of morphine-equivalent dose (MED) for ≥3 months. OUTCOME MEASURES: Self-reported clinical, medication (verified) and substance use, and urine drug testing (UDT) data were collected. RESULTS:Participants (N = 35) were 51.8 ± 9.7 years old, 80 percent female with CLBP for 14.2 ± 10.1 years, treated with opioids for 7.9 ± 5.7 years, with severe disability (Oswestry Disability Index score: 66.7 ± 11.4), and average pain score of 5.6 ± 1.5 (0-10 rating scale). Participants reported using tobacco (N = 14), alcohol (N = 9) and illicit drugs or unprescribed medications (N = 10). On average, participants took 13.4 ± 6.8 daily medications, including 4.7 ± 1.8 pain-modulating and 4.7 ± 2.0 sedating medications. Among prescribed opioids, 57.1 percent were long-acting and 91.4 percent were short-acting, with a total of 144.5 ± 127.8 mg/d of MED. Sixteen participants were prescribed benzodiazepines and/or zolpidem/ zaleplon. Fifteen participants had UDT positive for illicit drugs or unprescribed medications; in addition, eight tested positive for alcohol and 19 for cotinine. Compared to those with negative UDTs, those with positive UDTs (N = 15) received lower daily "total" and "extended release" opioid doses, and were more likely to test positive for cotinine (p < 0.05). CONCLUSIONS: Study findings corroborate existing evidence for high medication burden and high likelihood of substance misuse among opioid-treated CLBP patients. Further research is needed to help understand causality and ways to optimize care and clinical outcomes.
RCT Entities:
OBJECTIVE: Refractory chronic low back pain (CLBP) often leads to treatment with long-term opioids. Our goal was to describe the pharmaco-toxicological profile of opioid-treated CLBPpatients and identify potential areas for care optimization. DESIGN: Cross-sectional analysis. SETTING:Outpatient primary care. PARTICIPANTS: CLBPpatients prescribed ≥ 30 mg/d of morphine-equivalent dose (MED) for ≥3 months. OUTCOME MEASURES: Self-reported clinical, medication (verified) and substance use, and urine drug testing (UDT) data were collected. RESULTS:Participants (N = 35) were 51.8 ± 9.7 years old, 80 percent female with CLBP for 14.2 ± 10.1 years, treated with opioids for 7.9 ± 5.7 years, with severe disability (Oswestry Disability Index score: 66.7 ± 11.4), and average pain score of 5.6 ± 1.5 (0-10 rating scale). Participants reported using tobacco (N = 14), alcohol (N = 9) and illicit drugs or unprescribed medications (N = 10). On average, participants took 13.4 ± 6.8 daily medications, including 4.7 ± 1.8 pain-modulating and 4.7 ± 2.0 sedating medications. Among prescribed opioids, 57.1 percent were long-acting and 91.4 percent were short-acting, with a total of 144.5 ± 127.8 mg/d of MED. Sixteen participants were prescribed benzodiazepines and/or zolpidem/ zaleplon. Fifteen participants had UDT positive for illicit drugs or unprescribed medications; in addition, eight tested positive for alcohol and 19 for cotinine. Compared to those with negative UDTs, those with positive UDTs (N = 15) received lower daily "total" and "extended release" opioid doses, and were more likely to test positive for cotinine (p < 0.05). CONCLUSIONS: Study findings corroborate existing evidence for high medication burden and high likelihood of substance misuse among opioid-treated CLBPpatients. Further research is needed to help understand causality and ways to optimize care and clinical outcomes.
Authors: Laxmaiah Manchikanti; Rajeev Manchukonda; Vidyasagar Pampati; Kim S Damron; Doris E Brandon; Kim A Cash; Carla D McManus Journal: Pain Physician Date: 2006-04 Impact factor: 4.965
Authors: Edward Michna; Robert N Jamison; Loc-Duyen Pham; Edgar L Ross; David Janfaza; Srdjan S Nedeljkovic; Sanjeet Narang; Diane Palombi; Ajay D Wasan Journal: Clin J Pain Date: 2007-02 Impact factor: 3.442
Authors: Robert Taylor; Joseph V Pergolizzi; R Amy Puenpatom; Kent H Summers Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2013-12 Impact factor: 2.217
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: Kathryn Sullivan Dillie; Michael F Fleming; Marlon P Mundt; Michael T French Journal: J Am Board Fam Med Date: 2008 Mar-Apr Impact factor: 2.657
Authors: Aleksandra E Zgierska; Cindy A Burzinski; Jennifer Cox; John Kloke; Aaron Stegner; Dane B Cook; Janice Singles; Shilagh Mirgain; Christopher L Coe; Miroslav Bačkonja Journal: Pain Med Date: 2016-03-10 Impact factor: 3.750
Authors: Aleksandra E Zgierska; Cindy A Burzinski; Jennifer Cox; John Kloke; Janice Singles; Shilagh Mirgain; Aaron Stegner; Dane B Cook; Miroslav Bačkonja Journal: J Altern Complement Med Date: 2016-06-07 Impact factor: 2.579
Authors: Aleksandra E Zgierska; Regina M Vidaver; Paul Smith; Mary W Ales; Kate Nisbet; Deanne Boss; Wen-Jan Tuan; David L Hahn Journal: BMC Health Serv Res Date: 2018-06-05 Impact factor: 2.655
Authors: Charles E Argoff; Daniel P Alford; Jeffrey Fudin; Jeremy A Adler; Matthew J Bair; Richard C Dart; Roy Gandolfi; Bill H McCarberg; Steven P Stanos; Jeffrey A Gudin; Rosemary C Polomano; Lynn R Webster Journal: Pain Med Date: 2018-01-01 Impact factor: 3.750